TAXTOX – a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009

References

• Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007;CD004421.
   PubMed Web of Science ®Google Scholar
• Estevez LG, Munoz M, Alvarez I, Fernandez Y, Garcia-Mata J, Ruiz-Borrego M, . Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. Cancer Treat Rev 2007;33:474–83.
   PubMed Web of Science ®Google Scholar
• Bria E, Nistico C, Cuppone F, Carlini P, Ciccarese M, Milella M, . Benefit of taxanes as adjuvant chemotherapy for early breast cancer: Pooled analysis of 15,500 patients. Cancer 2006;106:2337–44.
   PubMed Web of Science ®Google Scholar
• De LM, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, . Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol 2008;26:44–53.
   PubMedGoogle Scholar
• Dang C, Hudis C: Adjuvant taxanes in the treatment of breast cancer: No longer at the tip of the iceberg. Clin Breast Cancer 2006;7:51–8.
   PubMed Web of Science ®Google Scholar
• Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A. Taxanes for the adjuvant treatment of early breast cancer: Systematic review and economic evaluation. Health Technol Assess 2007;11:1–144.
   Web of Science ®Google Scholar
• Lwin Z, Leighl N. Economic evaluation of docetaxel for breast cancer. Expert Opin Pharmacother 2009;10:283–90.
   PubMed Web of Science ®Google Scholar
• Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, . Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. J Clin Oncol 2006; 20;24:5664–71.
   Google Scholar
• Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, . Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trial. Clin Cancer Res 2002;8:1073–9.
   PubMed Web of Science ®Google Scholar
• Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, . Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976–83.
   PubMed Web of Science ®Google Scholar
• Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, . Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 2005;23:3686–96.
   PubMed Web of Science ®Google Scholar
• Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, . Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: Safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol 2008;19:853–60.
   PubMed Web of Science ®Google Scholar
• Gianni L, Baselga J, Eiermann W, Guillem P, Semiglazov V, Lluch A, . Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005;11:8715–21.
   PubMed Web of Science ®Google Scholar
• Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, . Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 2008; 100:805–14.
   PubMedGoogle Scholar
• Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, . Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24:5381–7.
   PubMed Web of Science ®Google Scholar
• Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, . Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27:1177–83.
   PubMed Web of Science ®Google Scholar
• Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, . Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302–13.
   PubMed Web of Science ®Google Scholar
• Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, . Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008;26:4092–9.
   PubMed Web of Science ®Google Scholar
• Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, . Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): An open-label, phase III, randomised controlled trial. Lancet 2009;373:1681–92.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, . Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial. J Clin Oncol 2009;27:5685–92.
   PubMed Web of Science ®Google Scholar
• Francis P, Crown J, Di LA, Buyse M, Balil A, Andersson M, . Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 2008;100: 121–33.
   PubMed Web of Science ®Google Scholar
• Papaldo P, Lopez M, Marolla P, Cortesi E, Antimi M, Terzoli E, . Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 2005; 23:6908–18.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol 2007;25:3158–67.
   PubMed Web of Science ®Google Scholar